Chiara Ambrogio

Spanish National Cancer Research Centre — Spain

Medicine · Health Sciences

40h-index5.0kcitations214works14.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(64), Lymphoma Diagnosis and Treatment(41), CAR-T cell therapy research(24), Chronic Lymphocytic Leukemia Research(22), Melanoma and MAPK Pathways(22)

Publications214 total

Correction: CCM-ITALUNG2 pilot on lung cancer screening in Italy: recruitment, integration with smoking cessation and baseline results
La radiologia medica·2025· 1 citedOpen Access
Abstract A076: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors
Molecular Cancer Therapeutics·2025
Abstract B055: XPO1-dependent nuclear export as a therapeutic target for ALK-positive non-small cell lung cancers
Molecular Cancer Therapeutics·2025
CCM-ITALUNG2 pilot on lung cancer screening in Italy: recruitment, integration with smoking cessation and baseline results
La radiologia medica·2025
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer
Cancer·2025· 3 citedOpen Access
Correction: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
Oncogene·2025Open Access
Abstract 4394: GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models
Cancer Research·2025· 3 cited
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS <sup>G12D</sup> inhibitor in KRAS LUAD
Proceedings of the National Academy of Sciences·2025· 4 citedOpen Access
ALK in cancer: from function to therapeutic targeting
Nature reviews. Cancer·2025· 18 cited
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
UNC Libraries·2025Open Access
Oncogenic mutant <scp>KRAS</scp> inhibition through oxidation at cysteine 118
Molecular Oncology·2025· 2 citedOpen Access
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment
Nature Communications·2025· 17 citedOpen Access
Targeted KRAS <sup>G12V</sup> degradation elicits efficient and durable lung adenocarcinoma regression <i>in vivo</i>
2024Open Access
scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers
Advanced Science·2024· 1 citedOpen Access
Author response for "Oncogenic mutant &lt;scp&gt;KRAS&lt;/scp&gt; inhibition through oxidation at cysteine 118"
2024
Contributors
Elsevier eBooks·2024Open Access
KRAS combination strategies: How well aligned is clinical and preclinical research?
Elsevier eBooks·2024· 1 cited
Experimental variables determine the outcome of RAS-RAS interactions
Journal of Biological Chemistry·2024· 6 citedOpen Access
Pharmacological SOS1 inhibitor BI-3406 demonstrates <i>in vivo</i> anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors
2024· 3 citedOpen Access
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Nature Communications·2024· 44 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Roberto Chiarle(29), Claudia Voena(19), Giorgio Inghirami(10), David Santamarı́a(9), Pasi A. Jänne(9), Cinzia Martinengo(9), Enrico Patrucco(7), Teresa Poggio(7), Cristina Mastini(7), Mariano Barbacid(6), Matteo Menotti(6), Luca Mologni(6), Roberto Piva(5), Taek-Chin Cheong(5), Ernest Nadal(5), Andrea D. Manazza(5), Mark M. Awad(5), Carlotta Costa(5), Emilio Hirsch(5), Inês Mota(5)